{"id":450597,"date":"2021-03-04T08:03:41","date_gmt":"2021-03-04T13:03:41","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=450597"},"modified":"2021-03-04T08:03:41","modified_gmt":"2021-03-04T13:03:41","slug":"fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/","title":{"rendered":"Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, March  04, 2021  (GLOBE NEWSWIRE) &#8212; Fortress Biotech, Inc. (NASDAQ: FBIO) (\u201cFortress\u201d), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in four virtual investor conferences in March 2021.<\/p>\n<p align=\"justify\">Details of the events are as follows:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">H.C. Wainwright Global Life Sciences Virtual Conference: The company\u2019s presentation will be available for on-demand viewing on Fortress\u2019 website beginning on Tuesday, March 9, 2021, at 7:00 a.m. ET and will remain available on the Events page under the News &amp; Media section of Fortress\u2019 website: <a href=\"http:\/\/www.fortressbiotech.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.fortressbiotech.com<\/a> for approximately 30 days following the presentation.<\/li>\n<li style=\"text-align:justify\">Barclays Global Healthcare Virtual Conference: The company will present on Thursday, March 11, 2021, at 3:00 p.m. ET and will participate in one-on-one meetings during the conference.<\/li>\n<li style=\"text-align:justify\">Virtual 33<sup>rd<\/sup> Annual ROTH Conference: The company will participate in a fireside chat on Tuesday, March 16, 2021, at 11:00 AM ET and will attend one-on-one meetings during the conference. A webcast of the fireside chat will be available on the Events page under the News &amp; Media section of Fortress\u2019 website: <a href=\"http:\/\/www.fortressbiotech.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.fortressbiotech.com<\/a> for approximately 30 days following the chat.<\/li>\n<li style=\"text-align:justify\">Oppenheimer 31<sup>st<\/sup> Annual Virtual Healthcare Conference: The company will present on Thursday, March 18, 2021, at 10:40 a.m. ET and will participate in one-on-one meetings during the conference.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>About Fortress Biotech <\/strong><br \/>\n        <br \/>Fortress Biotech, Inc. (\u201cFortress\u201d) is an innovative biopharmaceutical company that was ranked in Deloitte\u2019s 2019 and 2020 Technology Fast 500\u2122, annual rankings of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates. The company has five marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company\u2019s portfolio of product opportunities. Fortress has established partnerships with some of the world\u2019s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, St. Jude Children\u2019s Research Hospital and Nationwide Children\u2019s Hospital. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xr1olCrlObUX16KBgjxQWBEzp4UMGbHf5y6yb8BoJc4TEI1MTcFSIq4sgbV2bQPRgImmazms8XYaGP9FMT4ieCICBJqJD1znWPO9IdPVKkI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.fortressbiotech.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release may contain \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words \u201cwe\u201d, \u201cus\u201d and \u201cour\u201d may refer to Fortress individually or together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management\u2019s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; risks relating to the COVID-19 outbreak and its potential impact on our employees\u2019 and consultants\u2019 ability to complete work in a timely manner and on our ability to obtain additional financing on favorable terms or at all; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying <em>mutatis mutandis<\/em> to every other instance of such information appearing herein.<\/p>\n<p align=\"justify\">\n        <strong>Company Contacts:<\/strong><br \/>\n        <br \/>Jaclyn Jaffe and William Begien<br \/>Fortress Biotech, Inc.<br \/>(781) 652-4500<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DfPixAzkZZDEExgITu2DT6-axSF2JUjoOvc0HiClrurbZNdsrgxG9S4riwAegc9FqZZZvm3n1B5MBqroZ6v1IWW3Vp_uXn4zIPGtMENlfKw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@fortressbiotech.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Daniel Ferry<br \/>LifeSci Advisors, LLC<br \/>(617) 430-7576<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-msRXpeGqYmu1LudGoXyYghaqp34Lryz7wsb-WU0b8IF4k5f2jbgWwf1wfbuLtFs39eHho7jy9SqAcFS6fokm0qWWvhHJlKU8b0RldtIhW1Q4aA8USZ6ctZzcxmxDrmP\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">daniel@lifesciadvisors.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Relations Contact:<\/strong><br \/>\n        <br \/>Tony Plohoros<br \/>6 Degrees<br \/>(908) 591-2839<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Bf6k9vcZtUIFUvv0xKfpWk0bMGc_bBIEZw9DEqYnvaTk2CXsfHWl2EO2-8-y41VkNNStvs4WGLgfe1YFyQnbWstrnh0rTYwtJn2WgB1kGY4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>tplohoros@6degreespr.com<\/u><\/a>\u00a0\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDIyOSM0MDQ3ODk2IzIwMjY1NTI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/24528ac3-1ea9-4a2f-b733-a38b53abb1ea\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) &#8212; Fortress Biotech, Inc. (NASDAQ: FBIO) (\u201cFortress\u201d), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in four virtual investor conferences in March 2021. Details of the events are as follows: H.C. Wainwright Global Life Sciences Virtual Conference: The company\u2019s presentation will be available for on-demand viewing on Fortress\u2019 website beginning on Tuesday, March 9, 2021, at 7:00 a.m. ET and will remain available on the Events page under the News &amp; Media section of Fortress\u2019 website: www.fortressbiotech.com for approximately 30 days following the presentation. Barclays Global Healthcare &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-450597","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) &#8212; Fortress Biotech, Inc. (NASDAQ: FBIO) (\u201cFortress\u201d), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in four virtual investor conferences in March 2021. Details of the events are as follows: H.C. Wainwright Global Life Sciences Virtual Conference: The company\u2019s presentation will be available for on-demand viewing on Fortress\u2019 website beginning on Tuesday, March 9, 2021, at 7:00 a.m. ET and will remain available on the Events page under the News &amp; Media section of Fortress\u2019 website: www.fortressbiotech.com for approximately 30 days following the presentation. Barclays Global Healthcare &hellip; Continue reading &quot;Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-04T13:03:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDIyOSM0MDQ3ODk2IzIwMjY1NTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences\",\"datePublished\":\"2021-03-04T13:03:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\\\/\"},\"wordCount\":877,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDIyOSM0MDQ3ODk2IzIwMjY1NTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\\\/\",\"name\":\"Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDIyOSM0MDQ3ODk2IzIwMjY1NTI=\",\"datePublished\":\"2021-03-04T13:03:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDIyOSM0MDQ3ODk2IzIwMjY1NTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4NDIyOSM0MDQ3ODk2IzIwMjY1NTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences - Market Newsdesk","og_description":"NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) &#8212; Fortress Biotech, Inc. (NASDAQ: FBIO) (\u201cFortress\u201d), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in four virtual investor conferences in March 2021. Details of the events are as follows: H.C. Wainwright Global Life Sciences Virtual Conference: The company\u2019s presentation will be available for on-demand viewing on Fortress\u2019 website beginning on Tuesday, March 9, 2021, at 7:00 a.m. ET and will remain available on the Events page under the News &amp; Media section of Fortress\u2019 website: www.fortressbiotech.com for approximately 30 days following the presentation. Barclays Global Healthcare &hellip; Continue reading \"Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-04T13:03:41+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDIyOSM0MDQ3ODk2IzIwMjY1NTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences","datePublished":"2021-03-04T13:03:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/"},"wordCount":877,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDIyOSM0MDQ3ODk2IzIwMjY1NTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/","name":"Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDIyOSM0MDQ3ODk2IzIwMjY1NTI=","datePublished":"2021-03-04T13:03:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDIyOSM0MDQ3ODk2IzIwMjY1NTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4NDIyOSM0MDQ3ODk2IzIwMjY1NTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-to-participate-in-four-march-2021-virtual-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=450597"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/450597\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=450597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=450597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=450597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}